These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 10367173

  • 1. Preliminary phase II clinical and pharmacokinetic study of 9-cis retinoic acid in advanced cervical cancer. New York Gynecologic Oncology Group.
    Wadler S, Schwartz EL, Anderson P, Runowicz CD, Chuang L, Del Priore G, Hochster H, Goldberg G, Fields A, Loewen G, Haynes H.
    Cancer J Sci Am; 1999; 5(3):165-70. PubMed ID: 10367173
    [Abstract] [Full Text] [Related]

  • 2. A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study.
    Adamson PC, Widemann BC, Reaman GH, Seibel NL, Murphy RF, Gillespie AF, Balis FM.
    Clin Cancer Res; 2001 Oct; 7(10):3034-9. PubMed ID: 11595692
    [Abstract] [Full Text] [Related]

  • 3. 13-cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trial.
    Weiss GR, Liu PY, Alberts DS, Peng YM, Fisher E, Xu MJ, Scudder SA, Baker LH, Moore DF, Lippman SM.
    Gynecol Oncol; 1998 Dec; 71(3):386-90. PubMed ID: 9887236
    [Abstract] [Full Text] [Related]

  • 4. All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group.
    Wadler S, Schwartz EL, Haynes H, Rameau R, Quish A, Mandeli J, Gallagher R, Hallam S, Fields A, Goldberg G, McGill F, Jennings S, Wallach RC, Runowicz CD.
    Cancer; 1997 Apr 15; 79(8):1574-80. PubMed ID: 9118041
    [Abstract] [Full Text] [Related]

  • 5. Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid.
    Miller VA, Rigas JR, Benedetti FM, Verret AL, Tong WP, Kris MG, Gill GM, Loewen GR, Truglia JA, Ulm EH, Warrell RP.
    Clin Cancer Res; 1996 Mar 15; 2(3):471-5. PubMed ID: 9816192
    [Abstract] [Full Text] [Related]

  • 6. Phase I trial of all-trans retinoic acid in patients with treated head and neck squamous carcinoma.
    Park SH, Gray WC, Hernandez I, Jacobs M, Ord RA, Sutharalingam M, Smith RG, Van Echo DA, Wu S, Conley BA.
    Clin Cancer Res; 2000 Mar 15; 6(3):847-54. PubMed ID: 10741706
    [Abstract] [Full Text] [Related]

  • 7. Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer.
    Rizvi NA, Marshall JL, Ness E, Yoe J, Gill GM, Truglia JA, Loewen GR, Jaunakais D, Ulm EH, Hawkins MJ.
    Clin Cancer Res; 1998 Jun 15; 4(6):1437-42. PubMed ID: 9626460
    [Abstract] [Full Text] [Related]

  • 8. Related case report: in vivo suppression of thyrotropin by 9-cis retinoic acid.
    Dabon-Almirante CL, Damle S, Wadler S, Hupart K.
    Cancer J Sci Am; 1999 Jun 15; 5(3):171-3. PubMed ID: 10367174
    [Abstract] [Full Text] [Related]

  • 9. 9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-beta but no change in cyclooxygenase-2.
    Mernitz H, Smith DE, Zhu AX, Wang XD.
    Cancer Lett; 2006 Nov 28; 244(1):101-8. PubMed ID: 16413115
    [Abstract] [Full Text] [Related]

  • 10. Biological effects and metabolism of 9-cis-retinoic acid and its metabolite 9,13-di-cis-retinoic acid in HaCaT keratinocytes in vitro: comparison with all-trans-retinoic acid.
    Chen WC, Sass JO, Seltmann H, Nau H, Orfanos CE, Zouboulis CC.
    Arch Dermatol Res; 2000 Dec 28; 292(12):612-20. PubMed ID: 11214822
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.
    Nezhat F, Wadler S, Muggia F, Mandeli J, Goldberg G, Rahaman J, Runowicz C, Murgo AJ, Gardner GJ.
    Gynecol Oncol; 2004 Apr 28; 93(1):144-8. PubMed ID: 15047228
    [Abstract] [Full Text] [Related]

  • 12. Retinoids, cisplatin and interferon-alpha in recurrent or metastatic cervical squamous cell carcinoma: clinical results of 2 phase II trials.
    Braud AC, Gonzague L, Bertucci F, Genre D, Camerlo J, Gravis G, Goncalves A, Moutardier V, Viret F, Maraninchi D, Viens P.
    Eur Cytokine Netw; 2002 Apr 28; 13(1):115-20. PubMed ID: 11956030
    [Abstract] [Full Text] [Related]

  • 13. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
    Rose PG, Blessing JA, Van Le L, Waggoner S.
    Gynecol Oncol; 1998 Aug 28; 70(2):263-6. PubMed ID: 9740702
    [Abstract] [Full Text] [Related]

  • 14. Phase I trial of 9-cis retinoic acid in adults with solid tumors.
    Kurie JM, Lee JS, Griffin T, Lippman SM, Drum P, Thomas MP, Weber C, Bader M, Massimini G, Hong WK.
    Clin Cancer Res; 1996 Feb 28; 2(2):287-93. PubMed ID: 9816171
    [Abstract] [Full Text] [Related]

  • 15. Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer.
    Adamson PC.
    Leukemia; 1994 Feb 28; 8 Suppl 3():S22-5. PubMed ID: 7808020
    [Abstract] [Full Text] [Related]

  • 16. Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study.
    Hofmann WK, Kell WJ, Fenaux P, Castaigne S, Ganser A, Chomienne C, Burnett R, Kowal C, Hoelzer D, Burnett AK.
    Leukemia; 2000 Sep 28; 14(9):1583-8. PubMed ID: 10995004
    [Abstract] [Full Text] [Related]

  • 17. A phase I-II study of 9-cis retinoic acid and interferon-alpha2b in patients with advanced renal-cell carcinoma: an NCIC Clinical Trials Group study.
    Miller WH, Reyno LM, Loewen GR, Huan S, Winquist E, Moore M, Cato A, Jaunakais D, Truglia JA, Matthews S, Dancey J, Eisenhauer E.
    Ann Oncol; 2000 Nov 28; 11(11):1387-9. PubMed ID: 11142476
    [Abstract] [Full Text] [Related]

  • 18. Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.
    Sonawane P, Cho HE, Tagde A, Verlekar D, Yu AL, Reynolds CP, Kang MH.
    Br J Pharmacol; 2014 Dec 28; 171(23):5330-44. PubMed ID: 25039756
    [Abstract] [Full Text] [Related]

  • 19. Antitumoral activity of 13-demethyl or 13-substituted analogues of all-trans retinoic acid and 9-cis retinoic acid in the human myeloid leukemia cell line HL-60.
    Mizuguchi Y, Wada A, Nakagawa K, Ito M, Okano T.
    Biol Pharm Bull; 2006 Sep 28; 29(9):1803-9. PubMed ID: 16946489
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.
    Takekuma M, Hirashima Y, Ito K, Tsubamoto H, Tabata T, Arakawa A, Itani Y, Furukawa N, Murakoshi H, Takeuchi S.
    Gynecol Oncol; 2012 Sep 28; 126(3):341-5. PubMed ID: 22609108
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.